Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence both in children (15-30%) and adults (2-10%); limited data are available for the elderly. Elderly patients are challenging showing frequent multiple comorbidities, associated polypharmacy, and common previously treatments failure. We performed a retrospective observational study on elderly (≥ 65 year-old) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the IL4 and IL-13 receptor approved for the treatment of moderate-to-severe AD in adults.

Efficacy and safety of dupilumab in atopic dermatitis of the elderly: A retrospective study

Patruno, C
2020-01-01

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease with high prevalence both in children (15-30%) and adults (2-10%); limited data are available for the elderly. Elderly patients are challenging showing frequent multiple comorbidities, associated polypharmacy, and common previously treatments failure. We performed a retrospective observational study on elderly (≥ 65 year-old) patients treated with dupilumab, monoclonal antibody to the shared alpha subunit of the IL4 and IL-13 receptor approved for the treatment of moderate-to-severe AD in adults.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/61599
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact